However, it is controversial whether to perform NAC in HR-positive/HER2-negative BC patients who are eligible for BCS but with a tumor size of 2–5 cm or 1–3 lymph node metastases (Jiang et al. 2022; Spring et al. 2022). Here, ERBB2 is linked to neoplasm.